Sonnenschein Nath & Rosenthal LLP

Contact:
Venture Capital/Emerging Growth Companies:
Victor H. Boyajian
973.912.7171
212.768.5349
650.798.0300
John L. Cleary II
973.912.7171

Intellectual Property and Technology:
Harley Blosser
314.259.5806
Carol Anne Been
312.876.3122

Health Care:
Gadi Weinreich
202.408.9166
Chris Janney
202.408.9151


Overview
Print this page   Email this page to a colleague

Life SciencesSonnenschein is among the leading national law firms representing organizations and individuals whose principal business involves the funding, development, production, management, regulation, and advancement of technology and processes in the life sciences arena.  With more than 60 attorneys, scientists, patent agents and other specialists focused on the life sciences sector, we provide significant depth of expertise in nearly every aspect of the broadly defined industry.

Sonnenschein’s Life Sciences Industry Group spans the nation from industry hotbeds in Silicon Valley and San Diego to the Northeast, including New Jersey’s biotechnology “research corridor”.  This group is complemented by our specialized life sciences regulatory expertise in San Francisco, the Midwest and Washington, D.C.  Our client base includes some of the nation’s largest pharmaceutical, biotech, medical device, cleantech, leading life sciences-focused investment funds and venture capital funds, emerging growth companies, national laboratories, academic institutions, individual entrepreneurs and inventors.

Click here to read about Sonnenschein's Life Sciences Industry and Practice Group Expertise.



Spotlight on Life Sciences
Jeffrey Baumel Joins Sonnenschein
Jeffrey Baumel
Jeffrey A. Baumel, a nationally-recognized leader in the life sciences, biotech and technology company arenas, has joined the firm as Chair, Corporate Life Sciences practice.  Mr. Baumel works extensively with venture capital firms and underwriters in growth stage ventures, and also represents established, later-stage public and private companies in mergers and acquisitions and corporate, commercial and capital transactions.  Click here to read Baumel's news release.